Patents Assigned to Aprogen, Inc.
  • Patent number: 11820831
    Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: November 21, 2023
    Assignee: APROGEN INC.
    Inventors: Yoo Ri Moon, Sangsoon Yoon, Jeong Won Hong, Eun Jung Kim, Da Bin Choi
  • Patent number: 11542339
    Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: January 3, 2023
    Assignee: APROGEN INC.
    Inventors: Kwon Pyo Hong, Sangsoon Yoon, Irene Koukoulas, Vincent Batori, Briony Cristiano, David S Wilson, Jr., George Kopsidas
  • Patent number: 10259860
    Abstract: The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: April 16, 2019
    Assignee: APROGEN INC.
    Inventors: Hak-Zoo Kim, Young Jun Koh, Ho-Min Kim, Keehoon Jung, Choonjoo Jeon, Gou Young Koh
  • Publication number: 20140073566
    Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.
    Type: Application
    Filed: March 20, 2013
    Publication date: March 13, 2014
    Applicant: Aprogen, Inc.
    Inventor: Aprogen, Inc.
  • Patent number: 8426570
    Abstract: The present invention relates to a recombinant expression vector for an animal cell containing a dihydrofolate reductase (DHFR) coding nucleotide sequence operatively linked to a DHFR promoter, to an animal cell line transformed by the vector, and to a method for preparing a target protein using the same. As compared with existing animal cell expression vectors, the vector of the present invention enables an effective screening of a cell line clone in which foreign genes are amplified together with DHFR genes even at a much lower methotrexate concentration. The present invention exhibits excellent effects in cell line preparation as high-productivity cell lines can be ensured in a short time through the use of a lower concentration of methotrexate in the process of protein production cell line establishment.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: April 23, 2013
    Assignee: Aprogen Inc.
    Inventors: Keun Soo Kim, Hye Kyung Ju, Choon Ju Jeon, Jae Seob Kim
  • Patent number: 8420353
    Abstract: A humanized antibody is produced by process comprising the steps of: (a) selecting a specificity determining residue (SDR) of the complementarity determining region (CDR) of murine monoclonal antibody heavy chain and light chain variable regions; and (b) grafting said SDR to at least one of the corresponding amino acid sequences in human antibody variable regions.
    Type: Grant
    Filed: March 22, 2003
    Date of Patent: April 16, 2013
    Assignee: Aprogen, Inc.
    Inventors: Hyo Jeong Hong, Cheol-Young Maeng, Gi-Hyeok Yang, Meong Hee Jang, Mee Sook Oh, Jin-Soo Song, Young Kug Jang
  • Patent number: 8414877
    Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: April 9, 2013
    Assignee: Aprogen, Inc.
    Inventors: Gou Young Koh, Chung-Hyun Cho
  • Publication number: 20120251503
    Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.
    Type: Application
    Filed: May 17, 2012
    Publication date: October 4, 2012
    Applicant: Aprogen, Inc.
    Inventors: Gou Young KOH, Chung-Hyun Cho
  • Patent number: 8268316
    Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 18, 2012
    Assignee: Aprogen, Inc
    Inventors: Hyo Jeong Hong, Kyung Soo Inn, Nam Kyu Lim, Jung Whan Kim, Keun Soo Kim, Sang Yoon Lee, Se Yeon Kim, Hyun Jung Kang, Mee Sook Oh
  • Patent number: 8206698
    Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 26, 2012
    Assignee: Aprogen, Inc.
    Inventors: Gou Young Koh, Chung-Hyun Cho
  • Publication number: 20110117643
    Abstract: The present invention relates to a recombinant expression vector for an animal cell containing a dihydrofolate reductase (DHFR) coding nucleotide sequence operatively linked to a DHFR promoter, to an animal cell line transformed by the vector, and to a method for preparing a target protein using the same. As compared with existing animal cell expression vectors, the vector of the present invention enables an effective screening of a cell line clone in which foreign genes are amplified together with DHFR genes even at a much lower methotrexate concentration. The present invention exhibits excellent effects in cell line preparation as high-productivity cell lines can be ensured in a short time through the use of a lower concentration of methotrexate in the process of protein production cell line establishment.
    Type: Application
    Filed: July 7, 2009
    Publication date: May 19, 2011
    Applicant: Aprogen Inc.
    Inventors: Keun Soo Kim, Hye Kyung Ju, Choon Ju Jeon, Jae Seob Kim
  • Publication number: 20110117104
    Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.
    Type: Application
    Filed: March 10, 2006
    Publication date: May 19, 2011
    Applicant: Aprogen Inc.
    Inventors: Hyo Jeong Hong, Kyung Soo Inn, Nam Kyu Lim, Jung Whan Kim, Keun Soo Kim, Sang Yoon Lee, Se Yeon Kim, Hyun Jung Kang, Mee Sook Oh
  • Patent number: 7691366
    Abstract: The present application describes a fusion molecule that includes coiled coil domain, which renders the molecule soluble and provides potent activity.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: April 6, 2010
    Assignee: Aprogen Inc.
    Inventor: Gou Young Koh
  • Patent number: 7691365
    Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: April 6, 2010
    Assignee: Aprogen, Inc.
    Inventors: Gou Young Koh, Chung-Hyun Cho